Dexamethasone is associated with early deaths in light chain amyloidosis patients with severe cardiac involvement

BACKGROUND: Cardiac light chain amyloidosis (AL-CA) patients often die within three months of starting chemotherapy. Chemotherapy for non-immunoglobulin M gammopathy with AL-CA frequently includes bortezomib (Bor), cyclophosphamide (Cy), and dexamethasone (D). We previously reported that NT-ProBNP l...

Descripción completa

Detalles Bibliográficos
Autores principales: Bézard, Mélanie, Oghina, Silvia, Vitiello, Damien, Kharoubi, Mounira, Kordeli, Ekaterini, Galat, Arnault, Zaroui, Amira, Guendouz, Soulef, Gilles, Floriane, Shourick, Jason, Hamon, David, Audard, Vincent, Teiger, Emmanuel, Poullot, Elsa, Molinier-Frenkel, Valérie, Lemonnier, François, Agbulut, Onnik, Le Bras, Fabien, Damy, Thibaud
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8443042/
https://www.ncbi.nlm.nih.gov/pubmed/34525116
http://dx.doi.org/10.1371/journal.pone.0257189

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8443042/
https://www.ncbi.nlm.nih.gov/pubmed/34525116
http://dx.doi.org/10.1371/journal.pone.0257189

Ejemplares similares